Qualification Opinion and Qualification Advice are two distinct procedures offered by the European Medicines Agency for qualifying novel methodologies in medicinal product development. A CHMP Qualification Opinion confirms the acceptability of a specific use of a methodology based on submitted data. Qualification Advice, by contrast, assesses the scientific rationale and preliminary data of a methodology that is still on its way toward qualification.
Qualification of novel methodologies at the EMA
The EMA procedure addresses novel methodologies, such as biomarkers or imaging techniques, intended to generate evidence for regulatory benefit-risk assessments and decisions. They can be used in nonclinical or clinical studies and may apply to various stages of the product lifecycle. The Qualification of Novel Methodologies is a voluntary scientific pathway that supports the development, evaluation, and regulatory recognition of a methodology within a defined context.
The Committee for Medicinal Products for Human Use, or CHMP, makes the formal decision; its opinions are based on recommendations from the Scientific Advice Working Party. The EMA publishes all CHMP Qualification Opinions. Publicly available opinions can show researchers and developers the context in which a methodology has been accepted, without requiring every subsequent study to answer the same evidentiary questions from scratch.
Qualification Opinion, Advice, and Letter of Support
A Qualification Opinion addresses the acceptability of a specific use of a methodology. It is issued after review of the data submitted to the EMA; before final adoption, the CHMP makes its assessment available to the scientific community for public consultation. The Opinion is therefore tied to a clearly defined context of use, not a general certification that a biomarker is suitable for use in any medicinal product programme.
Qualification Advice, by contrast, concerns protocols and methodologies that are still being developed toward qualification. For this purpose, the EMA evaluates the scientific rationale and preliminary data. If the methodology is not yet ready for qualification but shows promise, the EMA may, on the basis of the Advice, propose a Letter of Support intended to encourage data sharing and further studies.
Distinction: the path to a regulatory accepted endpoint
A biomarker is a measurable biological characteristic; a digital biomarker uses digital technologies to perform such a measurement. A surrogate endpoint serves as a substitute endpoint in a study. None of these terms alone means that the EMA has accepted its use in a specific regulatory context. The qualification procedure is the bridge between the scientific development of a methodology and its regulatory recognition.
Qualification Advice should not be equated with general Scientific Advice. Scientific Advice can relate to the development of a specific medicinal product or an individual development plan. The Qualification Opinion and the Advice directed toward it, by contrast, address a methodology and its context of use, which may be relevant to various developers and study programmes.
In addition to classic laboratory and imaging markers, the procedure can also apply to methodologies that make data from other innovative sources usable. What matters is not the novelty of a technology in itself, but whether its intended context of use is clearly defined and supported by sufficient evidence. An Opinion is therefore formulated in a context-specific manner and should not be read as a general quality seal for a platform.
Relevance for clinical trials
For a study involving a novel biomarker, an early decision must be made as to whether the measurement method will remain purely exploratory or play a central role in decision-making, patient enrichment, or endpoint assessment. The evidence strategy must then align analytical performance, clinical relevance, intended purpose, and the data to be collected. An unclearly defined context of use can easily result in the available data not matching the regulatory question at hand.
Full-service CROs such as Mediconomics support qualification projects by translating the planned context of use into study protocols, biomarker data collection plans, and statistical evidence packages. Biostatistics can structure the rationale for the data basis and the analysis strategy, while Regulatory Affairs supports interaction with the EMA and the compilation of the submission documents. Clinical Operations ensures that sample logistics, imaging, or digital measurements at the trial site are compatible with the methodology being qualified.
Frequently Asked Questions (FAQ)
Does a Qualification Opinion confirm every use of a biomarker?
No. It concerns the acceptability of a specific use of the methodology. Outside this context, a separate scientific and regulatory justification may be required.
When is a Letter of Support appropriate?
It may follow Qualification Advice when a methodology cannot yet be qualified, but the preliminary data suggest it is promising.
Is Qualification Advice the same as the approval of a medicinal product?
No. The procedure evaluates a methodology for use in medicinal product development; it does not grant marketing authorisation for a specific medicinal product.
Regulatory References
- EMA Qualification of novel methodologies — Describes Opinion, Advice, and Letters of Support.
- EMA Procedural Guidance to applicants for QoNM — Governs the application procedure for novel methodologies.
- Regulation (EC) No 726/2004, Article 57(1)(n) — Legal basis for scientific advice and qualification.
- CHMP Qualification Opinions — Publishes the accepted contexts of use for qualified methodologies.